Comparison
Retatrutide vs tirzepatide: receptor targets compared
Both peptides come from the same research programme and both act at the GIP and GLP-1 receptors. Retatrutide adds a third target. Here is how the discovery papers describe each.
At a glance
| Tirzepatide | Retatrutide | |
|---|---|---|
| Development code | LY3298176 | LY3437943 |
| Receptors agonised | GIP receptor and GLP-1 receptor | Glucagon, GIP and GLP-1 receptors |
| In vitro profile described by the discovery paper | Imbalanced: greater engagement of the GIP receptor than the GLP-1 receptor; biased at the GLP-1 receptor toward cAMP over beta-arrestin recruitment | Balanced glucagon and GLP-1 receptor activity, with more GIP receptor activity |
| Molecular formula (PubChem) | C225H348N48O68, about 4813 g/mol | Not listed in PubChem under this name |
| Key papers | Willard et al., 2020 (JCI Insight) | Coskun et al., 2022 (Cell Metabolism) |
Tirzepatide
Willard et al. (2020) describe tirzepatide as a dual GIP and GLP-1 receptor agonist. Their receptor-occupancy analysis shows a greater degree of engagement of the GIP receptor than the GLP-1 receptor, which they call an imbalanced mechanism of action. Signalling studies show it mimics native GIP at the GIP receptor but shows bias at the GLP-1 receptor, favouring cAMP generation over beta-arrestin recruitment, with weaker receptor internalisation than native GLP-1.
Retatrutide
Coskun et al. (2022) describe LY3437943 as a triple agonist at the glucagon receptor, the GIP receptor and the GLP-1 receptor. In vitro it shows balanced glucagon and GLP-1 receptor activity but more GIP receptor activity. In obese mice, the reduction in body weight was augmented when glucagon-receptor-mediated increases in energy expenditure were added to the GIP and GLP-1 receptor-driven reduction in calorie intake.
Reading the two literatures side by side
Because both agents hit GIP and GLP-1 receptors, effects shared by the two cannot be assigned to the glucagon receptor, and effects that differ cannot be assigned to it either without a design that isolates it. The clinical programmes are published separately for each (for example the SURMOUNT-1 trial for tirzepatide and the phase 2 trial for retatrutide), and each trial population and endpoint should be read on its own terms.
Identity checks
For a peptide with no PubChem record under its name, the batch Certificate of Analysis is the main identity evidence: look for an observed mass from mass spectrometry that matches a theoretical value. See how to read a peptide COA.
Compound pages and tools
- Tirzepatide research peptide
- Retatrutide research peptide
- All GLP-1 and incretin research peptides
- Retatrutide reconstitution calculator
- Tirzepatide reconstitution calculator
Related
Further reading
References
- Willard FS, Douros JD, Gabe MB, et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5. PubMed 32730231 · DOI
- Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34:1234-1247.e9. PubMed 35985340 · DOI
- Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 389:514-526. PubMed 37366315 · DOI
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387:205-216. PubMed 35658024 · DOI
Frequently asked questions
What is the main difference between retatrutide and tirzepatide?
Tirzepatide agonises two receptors, GIP and GLP-1. Retatrutide agonises three: GIP, GLP-1 and glucagon. The added glucagon-receptor activity is the defining difference.
Are retatrutide and tirzepatide from the same company?
Both discovery papers are from Eli Lilly and Company authors (Willard 2020; Coskun 2022).